The DMTN Knockout SK-HEP-1 Polyclonal Cells represent a heterogeneous population of human hepatic adenocarcinoma cells engineered via CRISPR/Cas9-mediated disruption of the DMTN (dematin) gene. This polyclonal pool harbors diverse gene-editing outcomes across individual cells, providing a robust loss-of-function model without clonal selection biases. The resulting abrogation of dematin expression permits systematic investigation of actin cytoskeleton dynamics and membrane-associated signaling in a liver cancer background.
The SK-HEP-1 parental cell line is derived from a human liver adenocarcinoma and displays an epithelial morphology with adherent growth characteristics. Widely employed as a model for hepatic carcinogenesis, these cells retain key oncogenic signaling networks and exhibit migratory and invasive properties relevant to metastatic progression. Their compatibility with standard two-dimensional and three-dimensional culture formats renders them suitable for a range of molecular and cellular analyses.
Dematin functions as an actin-bundling protein that integrates multiple cytoskeletal regulatory inputs. It is phosphorylated by protein kinase A (PKA) and protein kinase C (PKC), and its expression is controlled by the erythroid transcription factor GATA1. Dematin directly binds actin filaments, spectrin, adducin, and band 3, facilitating the assembly of the spectrin?Cactin junctional complex and reinforcing membrane mechanical stability. Through these interactions, dematin influences Rho GTPase signaling cascades and modulates the organization of cortical actin networks. Disruption of DMTN uncouples these protein?Cprotein interfaces, leading to impaired actin filament bundling, altered spectrin?Cactin framework integrity, and compromised cytoskeletal anchorage at the plasma membrane.
In the context of SK-HEP-1 liver adenocarcinoma cells, DMTN knockout is particularly relevant for dissecting non-erythroid roles of dematin. Although originally characterized in erythrocytes, dematin is expressed in multiple tissues and has been implicated in cell adhesion, migration, and mechanical resilience. The loss of dematin in this hepatic cancer model permits direct assessment of how actin cytoskeletal perturbation impacts malignant phenotypes, including anchorage-independent growth, directional motility, and responsiveness to extracellular matrix cues. This system thus bridges erythrocyte membrane biology and cancer cytoskeletal pathophysiology.
Researchers can employ this knockout model in diverse experimental workflows. Phalloidin immunofluorescence visualizes gross actin organization changes, while western blotting for dematin, spectrin, and actin confirms protein depletion and downstream effects. Functional assays such as scratch wound healing and transwell invasion quantitatively measure migratory and invasive capacity, and cell adhesion assays evaluate attachment to matrix substrates. These applications support studies of actin-driven mechanisms in liver cancer progression and the exploration of dematin as a potential modulator of metastasis. For additional details or custom inquiries, please contact Ascent Research.
